Epigenetics in Psychiatry

Erscheinungsjahr 2014
ISBN: 978-0-12-417114-5
Verlag: Elsevier Science Publishing Co Inc

Buch, Englisch, 664 Seiten, Format (B × H): 184 mm x 241 mm, Gewicht: 1516 g

Epigenetics in Psychiatry covers all major areas of psychiatry in which extensive epigenetic research has been performed, fully encompassing a diverse and maturing field, including drug addiction, bipolar disorder, epidemiology, cognitive disorders, and the uses of putative epigenetic-based psychotropic drugs. Uniquely, each chapter correlates epigenetics with relevant advances across genomics, transcriptomics, and proteomics. The book acts as a catalyst for further research in this potentially very important and useful area of psychiatry.

The elucidation of basic principles of epigenetic biology points to the creation of more optimal and effective therapies for major classes of psychiatric disease. In this regard, epigenetic therapy, the use of drugs to correct epigenetic defects, may help in the pharmacotherapy of patients with these disorders. With time, such advances may eventually point to replacements for psychotropic drugs presently of symptomatic value and low efficacy. Moreover, there is evidence to suggest that other forms of treatment commonly used in the management of psychiatric disorders, like psychotherapy and electroconvulsive therapy, may also act by epigenetic mechanisms.

Zielgruppe

<p>This work is aimed at biomedical researchers of graduate level and above who are seeking to elucidate the epigenetic basis of psychiatric disorders. These researchers typically fall within biological psychiatry, neuroscience, epigenetics, molecular biology, and geneticists working on psychiatric disease. </p>

Autoren/Hrsg.

Peedicayil, Jacob

Grayson, Dennis R.

Avramopoulos, Dimitri

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften Neurobiologie, Verhaltensbiologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Humangenetik

Inhaltsverzeichnis

1. Introduction
2. Outline of Epigenetics
3. History of Epigenetics in Psychiatry
4. Role of Epigenetics in the Neural Stem Cell and Neuron
5. Role of Epigenetics in the Brain
6. Epigenetic Epidemiology of Psychiatric Disorders
7. Laboratory Techniques in Psychiatric Epigenetics
8. Laboratory Models in Psychiatric Epigenetics

9. DNA Methylation and Histone Changes in Schizophrenia
10. Non-Coding RNAs and Major Psychosis
11. Epigenetics and Bipolar Disorder
12. Epigenetics and Major Depressive Disorder
13. Epigenetics and Suicide
14. Epigenetics of Anxiety Disorder and Post-Traumatic Stress Disorder
15. Epigenetics and Cognitive Disorders
16. Epigenetics and Mental Retardation
17. Epigenetics of Pervasive Developmental Disorders and ADHD
18. Epigenetics and Drug Addiction
19. Epigenetic Effects of Currently-Used Psychotropic Drugs
20. Drugs Affecting DNA Methylation in Psychiatric Disorders
21. Histone Deacetylase Inhibitors and Psychiatric Disorders
22. The Social Environment and Epigenetics in Psychiatry
23. Nutritional Influences on Epigenetics in Psychiatry
24. Transgenerational Epigenetics and Psychiatric Disorders

Über Autor(innen)

Grayson, Dennis R.
Dr Dennis R. Grayson received his PhD from the Department of Biochemistry at Wayne State University School of Medicine in 1984. He has been interested in mechanisms associated with gene expression for over 35 years. He joined the laboratory of Dr James E. Darnell at the Rockefeller University as a Post-Doctoral Fellow in 1984 to study cell-type specific transcription factors and their interaction with promoters and enhancers. In 1988, Dr Grayson joined the Fidia-Georgetown Institute for the Neurosciences at Georgetown University to study gene expression programs in neurons and continued this research program at Allegheny Singer Research Institute in Pittsburgh from 1995 to 1998. He continued his interests in psychiatry and joined the Psychiatric Institute at the University of Illinois in 1998. This represented a unique opportunity to pursue the molecular underpinnings of schizophrenia. Dr Grayson has received NRSA post-doctoral support, and R01 and K04 funding from the National Institutes of Health to support his work. He has published over 140 papers in peer-reviewed journals and is regularly invited to speak at numerous national and international meetings. He is currently Director of the Epigenetic Core of the Center for Alcohol Research in Epigenetics.

Peedicayil, Jacob
Dr Jacob Peedicayil completed MBBS in 1984 and MD in pharmacology in 1991, both at the Christian Medical College, Vellore, India. From 1993 to 1995 he did a Post-Doctoral Fellowship at the Centre for Cellular and Molecular Biology, Hyderabad, India. From 1995 to 1998 he worked as a Research Fellow in the Department of Neurological Sciences, Christian Medical College, Vellore. Since 1998 he has been on the faculty of the Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, becoming a professor in 2007. He does theoretical research on epigenetics, focusing on epigenetics in psychiatry. In addition, he is involved in experimental research in smooth muscle pharmacology.

Avramopoulos, Dimitri
Dr. Dimitrios Avramopoulos received his MD from the University of Athens, Greece in 1990 and his PhD from the University of Crete in 1995 for his work on mapping human genes on chromosome 21 and deciphering the origin of chromosomal non-disjunction in trisomy 21, mentored by Dr Stylianos Antonarakis. He undertook his post-doctoral work at Johns Hopkins University where he became a faculty member in the Department of Psychiatry in 2002. He is currently on the faculty of the Department of Genetic Medicine and the Department of Psychiatry at Johns Hopkins University where he works on the genetics of psychiatric disorders. He is interested in the identification and functional follow up of disease-causing variants in the genome. He uses cellular models and genome editing to decipher the mechanisms through which disease - associated variants affect the brain, individually or in combinations, through the disruption of functional networks and the regulation of the corresponding genes.